Clinical Trial Results:
A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carriers)
Summary
|
|
EudraCT number |
2021-002687-41 |
Trial protocol |
NL |
Global end of trial date |
01 Jun 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Apr 2025
|
First version publication date |
06 Apr 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
TA-8995-AD-1
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05161715 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
NewAmsterdam Pharma BV
|
||
Sponsor organisation address |
Gooimeer 2-35, DC Naarden, Netherlands, 1411
|
||
Public contact |
Study Director, NewAmsterdam Pharma BV, 31 352062971, study.director@newamsterdampharma.com
|
||
Scientific contact |
Study Director, NewAmsterdam Pharma BV, +31 352062971, study.director@newamsterdampharma.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Aug 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 May 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jun 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this study is to evaluate the pharmacodynamics (PD) (apolipoproteins/lipid particles and cholesterol efflux) of obicetrapib in cerebrospinal fluid (CSF) and plasma (apolipoproteins/lipid particles) in patients with early Alzheimer’s Disease (AD) (hetero/homozygote APOE4 carriers).
The exploratory objectives of this study are to evaluate:
• other PD markers of obicetrapib (additional lipoproteins, neurodegeneration, and inflammation) in patients with early AD.
• the cognitive effects of obicetrapib in patients with early AD.
• the pharmacokinetics (PK) of obicetrapib in patients with early AD.
The safety objective of this study is to evaluate the safety and tolerability of obicetrapib in patients with early AD.
|
||
Protection of trial subjects |
The study was conducted in accordance with the Declaration of Helsinki and with all applicable laws and regulations of the locale and country where the study was conducted, and in compliance with Good Clinical Practice Guidelines.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Jan 2022
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 13
|
||
Worldwide total number of subjects |
13
|
||
EEA total number of subjects |
13
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
5
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
13 participants were randomized | ||||||
Pre-assignment
|
|||||||
Screening details |
18 participants were screened | ||||||
Period 1
|
|||||||
Period 1 title |
Overall Study
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Obicetrapib | ||||||
Arm description |
Obicetrapib (10 mg) | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Obicetrapib 5 mg tablet
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Once daily 2 x 5 mg obicetrapib tablet
|
||||||
|
|||||||
Period 2
|
|||||||
Period 2 title |
Overall Study
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Obicetrapib | ||||||
Arm description |
Obicetrapib (10 mg) | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Obicetrapib 5 mg tablet
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Once daily 2 x 5 mg obicetrapib tablet
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Obicetrapib
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Obicetrapib (10 mg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Obicetrapib
|
||
Reporting group description |
Obicetrapib (10 mg) | ||
Reporting group title |
Obicetrapib
|
||
Reporting group description |
Obicetrapib (10 mg) | ||
Subject analysis set title |
Baseline Population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Baseline Population is defined as all participants who received at least one dose of study drug.
|
|
|||||||||||||
End point title |
1. Mean Percent Change in Apolipoprotein A-I (ApoA-I) In Cerebrospinal Fluid (CSF) | ||||||||||||
End point description |
Mean percent change from screening (V1) to end of treatment (V6) in ApoA-I in CSF
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 weeks
|
||||||||||||
|
|||||||||||||
Notes [1] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF [2] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
Obicetrapib v Obicetrapib
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.425 [3] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [3] - No multiple testing correction was performed |
|
|||||||||||||
End point title |
2. Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma | ||||||||||||
End point description |
Mean percent change in ApoA-I in plasma from baseline (V2) to week 24 (V6)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 weeks
|
||||||||||||
|
|||||||||||||
Notes [4] - For the PD endpoints in plasma, analyses were conducted on all 13 patients. |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
Obicetrapib v Obicetrapib
|
||||||||||||
Number of subjects included in analysis |
26
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [5] | ||||||||||||
P-value |
= 0.0002 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [5] - No multiple testing correction was performed |
|
|||||||||||||
End point title |
3. Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF) | ||||||||||||
End point description |
Mean percent change from screening (V1) to end of treatment (V6) in ApoE
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 weeks
|
||||||||||||
|
|||||||||||||
Notes [6] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF [7] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
Obicetrapib v Obicetrapib
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0424 [8] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [8] - No multiple testing correction was performed |
|
|||||||||||||
End point title |
4. Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma | ||||||||||||
End point description |
Mean percent change from baseline (V2) to week 24 (V6) in plasma in ApoE
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 weeks
|
||||||||||||
|
|||||||||||||
Notes [9] - For the PD endpoints in plasma, analyses were conducted on all 13 patients. |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
Obicetrapib v Obicetrapib
|
||||||||||||
Number of subjects included in analysis |
26
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.001 [10] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [10] - No multiple testing correction was performed |
|
|||||||||
End point title |
5. Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline [11] | ||||||||
End point description |
Small high-density lipoprotein (s-HDL) particle concentration in cerebrospinal fluid (CSF) measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Baseline
|
||||||||
Notes [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Average relative abundance was reported and statistical analysis was not performed. Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649) |
|||||||||
|
|||||||||
Notes [12] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
6. Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24 [13] | ||||||||
End point description |
Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Week 24
|
||||||||
Notes [13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Average relative abundance was reported and statistical analysis was not performed. Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649) |
|||||||||
|
|||||||||
Notes [14] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
7. Small HDL (s-HDL) Particle Concentration in Plasma at Baseline [15] | ||||||||
End point description |
Small high-density lipoprotein (s-HDL) particle concentration plasma measured by Ion Mobility Assay.
For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Baseline
|
||||||||
Notes [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to a non-optimal sample preparation procedure, a number of the samples allocated for the small HDL-C particle analysis were lost and therefore no samples were assessed for this measure. |
|||||||||
|
|||||||||
Notes [16] - Due to a non-optimal sample prep, samples were not able to be assessed for this measure. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
8. Small HDL (s-HDL) Particle Concentration in Plasma at Week 24 [17] | ||||||||
End point description |
Small high-density lipoprotein (s-HDL) particle concentration in plasma measured by Ion Mobility Assay at Week 24
For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Week 24
|
||||||||
Notes [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to a non-optimal sample preparation procedure, a number of the samples allocated for the small HDL-C particle analysis were lost and therefore no samples were assessed for this measure. |
|||||||||
|
|||||||||
Notes [18] - Due to a non-optimal sample prep, samples were not able to be assessed for this measure. |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
9. Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF) | ||||||||||||
End point description |
Mean percent change in cholesterol efflux capacity in CSF from screening (V1) to week 24 (V6)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 Weeks
|
||||||||||||
|
|||||||||||||
Notes [19] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF [20] - Lumbar puncture was not possible for 1 patient at EOT (Day 168, Visit 6); hence n=12 for CSF |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
Obicetrapib v Obicetrapib
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.556 [21] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [21] - No multiple testing correction was performed |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From first dose of study drug through Week 24.5
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety Population included all participants who received at least 1 dose of any study drug.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
26.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Obicetrapib
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Obicetrapib (10 mg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |